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Streptomycin resistance in both gram-positive and gram-
negative bacteria is usually caused by a single mutation in
the rpsL gene.The rpsL gene encodes the S12 protein of
the ribosomal complex.The rpsL genes of various bacteria
have consensus regions in their sequences.Primers were
designed from these consensus pockets and a fragment of the
rpsL gene was sequenced from S. gordonii using PCR based
methodologies.Using the Multiplex Restriction Sequence
PCR(mRS PCR), which used the known primer at one end and a
restriction site primer on the other, a gene walk was
conducted.In streptomycin resistant strains of S.
gordonii, namely GP204, SP204 and SP635, the AAA coding for
Lys56 was mutated to ACA, coding for Thr56. The lysine to
Redacted for Privacythreonine transition, causing resistance to streptomycin
was identical to that expected from the literature.
The streptomycin resistance gene of S. pyogenes was
mapped using similar techniques. Streptomycin resistant
strains S43 ATCC, 543/192/4 and S43/192/30R were studied.
In streptomycin resistant S43 ATCC and S43/192/30R strains,
the lysine 56 changed to isoleucine and threonine
respectively.Surprisingly, the 192/4 had two mutations,
in each of the two hotspots in the rpsL gene where
mutations due to streptomycin resistance occur.It had the
amino acid 56, lysine, mutated to arginine and lysine 101
changed to asparagine.To check if this mutation was
stable in the host animal, S43/192/4 P8 (S43/192/4 passaged
eight times in mice) was sequenced and the sequence was
identical to the streptomycin resistant 192/4.Hence, the
lys101 mutation was stable and unlike the ancillary
mutations in E.coli and S. typhimurium, which are
compensated by new mutations.
The pathogenesis of S. pyogenes depends in part on the
ability of the pathogen to adhere to the epithelial cells
of the throat and the quantity of M protein.Pathogenesis
studies done on mice revealed the avirulence of S43/192/4smR
strain.To elucidate the reason for this avirulence, the
adherence properties and the production of M protein of thetwo strains S43/192/4smR and S43/192/30R were tested.
Qualitative immunoblot analysis of the M protein of 192/4
and 30R revealed no significant difference.Competition
ELISA was conducted to quantitate the M protein, and this
also did not show any significant difference in the M
protein levels. The adherence of 30R and 192/4 was measured
on human pharyngeal epithelial cell line.The adherence
properties of S43/192/4 SmR, was no different from other
strains in this experiment.Electron microscopy, using
immunogold to highlight the M protein on the cell surface
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CHAPTER 1
THESIS INTRODUCTION
Streptococcal disease and the need for a vaccine
In 1920, Homer Smith reported," As rheumatic fever
is not generally reportable, it is impossible to obtain
accurate statistics as to its incidence.It is very
widespread in its occurrence and is found in practically
all countries..." Today rheumatic fever is still the
leading cause of heart disease in developing countries,
particularly in school-age children and continues to
cause disease sporadically in the developed world.
Streptococcus pyogenes causes both the common "strep
throat" (pharyngitis) and the sequelae to pharyngitis
including rheumatic fever.The spectrum of diseases
caused by S. pyogenes range from mild to life-
threatening.Of particular importance is that in recent
years, there have been reports of highly invasive2
strains of S. pyogenes that cause necrotizing fasciitis.
This pathology has given Streptococcus the label in
popular press as the "flesh eating bacterium".Group A
streptococcus also causes scarlet fever, streptococcal
toxic shock syndrome, erysipelas, pyoderma, acute
rheumatic fever, glomeruionephritis and a variety of
other diseases (Fischetti et al., 1997).
Looking back at the history of streptococcal
research, it took more than a quarter of a century to
determine unequivocally that group A streptococcus
causes rheumatic fever.Through the detailed research
of Rebecca Lancefield, the pathogenic streptococci with
their complex antigenic structure were grouped, which
served as the basis for much future research.The
virulence of group A streptococcus is determined by a
variety of structural molecules, toxins and enzymes.Of
primary importance are the hyaluronic acid capsule,
exotoxins, streptolysins, streptokinases and perhaps
most importantly, the M protein.The surface-located M
protein, a a-helical coiled-coil fibrillar molecule,
confers to the organism the ability to resist phagocytic
attack (Fischetti et al., 1989).The serotypes of the M3
protein vary tremendously with more than 200 currently
recognized by the Center for Disease Control (CDC).
Though streptococcal disease is caused by a large number
of serotypes, M3 and M18 strains are the most common in
the U.S, causing rheumatic fever and Ml, M3 and M18
responsible for most invasive disease.The pathogen is
spread by person-to-person contact via respiratory
droplets.Transient colonization of the throat also
occurs.It is estimated that 15 to 20% of the normal
population are carriers for the Group A streptococcus
(Murray et al., 1994).
Although the importance and need for a vaccine
against S. pyogenes is well documented, as the antigens
of S. pyogenes vary widely with serotypes, development
of a successful vaccine has proved elusive.There was
also some complacency within the medical research
community because the group A streptococcus continues to
be relatively sensitive to penicillin.Hence, the
development of a vaccine was not a priority in many
developed countries.However, with the appearance of
enterococci resistant to penicillin-based antibiotics,
the stage is set for the group A streptococcus to
acquire this characteristic, with potentially disastrous4
consequences.Furthermore, the reticence of medical
practitioners to prescribe antibiotics for l`routine"
sore throats may lead to increasedpost streptococcal
sequelae, such as rheumatic fever.It thus becomes
imperative that streptococcal infections are prevented;
an effective vaccine needs to bedeveloped against
Streptococcus pyogenes.
History of vaccines
Vaccination originated just over 200 years ago when
Dr.Edward Jenner experimentally tested the folklore-
based notion that human infection with a mild bovine
pathogen called cowpox would protect infected
individuals against human smallpox.Thus was discovered
the principle of vaccination.Vaccination protects the
recipient from pathogenic agents by establishing an
immunological resistance to infection.An injected or
oral vaccine induces the host to generate antibodies
against the pathogen; therefore, during future exposures
the ability of the pathogen to cause disease is limited
by the immune system (Janeway et al., 1997).5
Modern vaccines typically consist of either a
killed or a live, nonvirulent (attenuated) form of the
infectious agent.Traditionally, the infectious agent
is grown in culture, purified, and either inactivated or
attenuated without losing the ability to evoke an immune
response that is effective against the virulent
infectious organism.
Although this procedure has demonstrated success
against many diseases, there are limitations.
1. Not all-infectious agents can be grown in
culture; hence, no vaccines have been developed for a
number of diseases, such as Mycobacterium leprae.
2. Complete immunity is not developed by the body when
vaccines are injected.Induction of local immune
responses characterized by IgA, requires mucosal
presentation.
3. Attenuated strains may revert, as was seen with polio
vaccine in Germany in the early phases of the mass
vaccination program during the 1950s.
4. Inactivation may be incomplete and the handling of
large volumes of the pathogen creates many safety
hazards.6
Recombinant DNA technology has provided a means of
creating a new generation of vaccines that overcomethe
drawbacks of traditional vaccines.Virulence genes
could be deleted from an infectious agent that retains
the ability to stimulate an immunological response.
This is theoretically safe, as it is impossible to
acquire a whole set of genes.
Bacterial commensal vectors
To circumvent some of the safety and environmental
issues inherent in the wide scale dissemination of
engineered pathogens, non- pathogenic vectors have been
developed.This delivery system is referred to as the
bacterial commensal vaccine.Live nonpathogenic carrier
systems that encode discrete antigenic determinants of a
pathogenic agent can be created.In this form, the
carrier system facilitates the induction of a strong
immunological response against the pathogen.Non-
pathogenic gram-positive vectors were developed which
stimulate a mucosal immune response at the site at which7
the pathogen enters the mammalianhost, with the
ultimate aim of blocking infection atthis site (Pozzi
et al., 1992b),(Fischetti et al., 1993).The system
enables the display of foreign antigens onthe bacterial
surface (Medaglini et al., 1995).Thus, gram-positive
oral commensal bacteria expressingrecombinant fusion
proteins on their cell surface have beensuccessfully
used to raise both a mucosal and a systemicimmune
response to foreign antigenswhile colonizing the
oropharynx, respiratory tract or vaginal mucosa(Bessen
et al., 1990) (Fischetti et al., 1993).
Several approaches are being explored to produce an
effective vaccine against S. pyogenes.Although the
antigens of this bacterium vary considerably, there are
certain epitopes within the M protein, which arehighly
conserved.These epitopes are the immunogenic component
of at least one prototype vaccine.Other methods are
the vaccines targeting different parts such as the
surface molecule C5a peptidase, the group carbohydrate,
or the secreted streptococcal protease(Spe B).
The M protein is immunogenic and the formation of
antibodies against M protein is essential to limit
infection.Disease occurs when strains establish an8
infection in the pharynx before specific systemic
antibodies develop.When designing a vaccine, it is
important to remember that an IgA inducing mucosal
vaccine should be the most effective vaccine.When S.
pyogenes colonizes the oropharynx,the IgA of the mucosa
would prevent the disease whilst the IgG in the body
would not be exposed to the pathogen until the disease
has progressed and the pathogen is disseminatingthrough
the blood stream (McGhee et al., 1993).
An important criterion in vaccine design was to
choose the vaccine design.Commensal vaccines, as
discussed earlier, remove many of the inherent dangers
associated with using the pathogen.With S. pyogenes
vaccine, Streptococcus gordonii was an attractive
choice.S. gordonii, formerly known as S. sanguis
belongs to Lancefield's group H.It is also commonly
referred to as the "Challis" strain.S. gordonii is a
commensal bacterium isolated from the human oral cavity
and was found to be naturally competent for genetic
transformation (Pozzi et al., 1987)(Pozzi et al.,
1990) .
A recombinant S. gordonii was constructed which
expresses the conserved C repeat region of S. pyogenesM9
protein.A pSMB104 nla.:Inid construct was made: pSMB104
emm-6.14104,a gene encoding for the245 amino acid M6Alo4
protein containing the first 16 N-terminal and the last
220 C-terminal amino acids of M6 (Bessen et al, 1990),
(Oggioni et al., 1996).This construction lacks the
serotypically diverse immunodeterminant epitopes that
have thwarted previous vaccine development efforts.
This plasmid was transfolnied into S. gordonii Challis
where theemm-6.14104gene integrated into the bacterial
chromosome (Bessen et al., 1989)(Bessen et al., 1995).
Thus, the recombinant. S.gordonii expressed the C repeat
region on the bacterial surface, inducing IgA and IgG
when introduced into animals (Myscofski et al., 1998)
(Medaglini et al., 1995)(Fischetti et al., 1993)
(Fischetti et al., 1996)(Fischetti et al., 1997).
Any live vaccine candidate needs a marker to
identify the vaccine strain and to differentiate the
vaccine strain from the naturally occurring commensal
strain, both during growth in the laboratory and in the
immunized target species.The important attribute of a
marker is to easily identify and differentiate the
vaccine strain from other strains.Antibiotic markers10
have been markers of choice as the antibiotic resistance
is easily identifiable on the basis of growth of a
colony on a plate.Care must be exercised to see that
this antibiotic resistance is not transferable to the
other bacteria in the environment and hence a plasmid
marker is not advisable.Care should also be taken to
see that the antibiotic used does not give anyadvantage
to the vaccine strains.
Streptomycin resistance was chosen as the
antibiotic resistance marker in S. gordonii, because
streptomycin is neither used prophylactically in any
streptococcal infection, nor commonly prescribed in
general.Further in the literature studies, most
streptomycin resistance in both gram-negative and gram-
positive bacteria is shown to be caused by a single
mutation in the rpsL gene (Salles et al., 1993).Thus
as a chromosomal mutation caused the resistance,it was
not readily transferable.11
Streptomycin Resistance
Waksman discovered streptomycin in 1943.Since
then, several aminoglycosides have been added to the
impressive array of antibiotics.The mode of action of
aminoglycosides is that they bind irreversibly to the
30S bacterial ribosome.This binding interferes with
the translation of the genetic code, and inhibits
synthesis of protein.An essential prelude to ribosomal
binding is an energy and oxygen-dependant transport
mechanism that is inhibited by anaerobiosis and low pH.
The uptake of aminoglycosides for various organisms,
specifically gram-positive cocci is facilitated by the
presence of inhibitors of synthesis of the bacterial
cell wallthat is, 0 lactam antibiotics and vancomycin.
Microbial resistance against aminoglycosides is
mediated through the followingmechanisms: a plasmid-
mediated aminoglycoside-modifying enzymes, reduced
transport into the cell and a ribosomal mutation that
results in reduced affinity for the 30S subunit.The
last mentioned mechanism is primarily demonstrated for
streptomycin (Mayo Clin Proc, 1999).12
In most bacteria, point mutations which cause
streptomycin resistance occur in the rpsL gene.The
rpsL gene encodes the conserved rpsl2 or the S12protein
of the ribosomal accuracy center (Tolvonen et al.,
1999).The ribosome accuracy center is a highly
conserved component of the cellular apparatus of
translation.This comprises a ribosomal RNA domain (16S
RNA) and several polypeptides of the small subunit
including S12, S4, ands S5 (E.coli nomenclature)(Alksne
et al., 1993).As discussed earlier, streptomycin
causes a decrease in the translationalfidelity of the
ribosome (Garvin et al., 1974), probably by inhibiting
its proof-reading mechanism.Mutations in S12 protein
alleviate this effect.These mutations reduce the
affinity of the ribosome for streptomycin and result in
a slower rate of translation, with a concomitant
increase in translational accuracy (Galas and Branscomb,
1976).Mutations that occur in S4 and S5 proteins,
called ribosomal ambiguity mutations (ram), cause an
opposite effect, increasing the affinity for
streptomycin (Bock et al., 1979) and causing a
relaxation in the translational fidelity of the ribosome
(Andersson and Kurland, 1983).13
Stern et al (1988) identified the sites of
interaction between 16S RNA and S12 protein;
interestingly, this region is adjacent to the putative
site for streptomycin interaction.Hence, mutations in
S12 that promote streptomycin resistance may protect the
streptomycin-binding site in the RNA (Timms et al.,
1993).In streptomycin resistant mutants, the rate of
formation and the initial complex between a near cognate
tRNA and the ribosome was decreased.The proof-reading
control, as assessed by the amount of GTP consumed per
erroneous incorporation, was increasedwith ribosomes
from streptomycin resistant mutants.The association
between subunits was loosened in ribosomes, since they
dissociate more readily than wild type ribosomes upon
heating (Phoenix et al., 1983).Gorini showed that
ribosomal protein mutations conferring resistance to
streptomycin in E.coli sometimes caused hyperaccurate
translation (Rondanelli et al., 1964).These mutations
were found frequently in the ribosomal protein S12and
occurred on specific residues.Later work established
that mutations in proteins S4 and S5 caused increased
sensitivity to streptomycin and a loss of translational
accuracy.14
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Introduction
A traditional method of identifying a bacterial gene
function is to transform bacteria that lack this function
(i.e., a mutant), with plasmids containing a library of
small fragments of the chromosomal DNA from a wild type
bacterium.If the DNA fragment in the plasmid
complements the missing function, the transformed
bacteria will grow as wild type under selection.The
rescuing fragment can then be sequenced and the nature of
the encoded gene product deduced by the use of
bioinformatics (Sambrook et al., 1989).Another method
has recently emerged for identifying genes that are
predicted to have conserved sequences.Complementary
primers are designed from these conserved regions and a
portion of the gene is excised and sequenced using the
polymerase chain reaction (PCR).l'Gene walking" is then
used to pull out the whole gene.The advantages of this
method are that it is quick and easy to perform.The
limitations of this method are the availability of
conserved sequences for the gene of interest and good
techniques in PCR and gene walking.Streptomycin16
sensitivity is dominant and hence the gene encoding
streptomycin resistance might be difficult to identify in
the library technique.Both the library method and the
PCR technique have worked in identifying the rpsL gene in
various bacteria (Salles et al 1992; Nair et al 1993).
Most of the streptomycin resistance in gram positive and
gram-negative bacteria is caused by a mutation in the
rpsL gene.By comparing the rpsL gene from various
bacteria, it is evident that there are conserved regions
in the gene, as shown in Figure 2.1.Not surprisingly,
just as certain parts of the gene are conserved, the
mutations that occur in this gene to confer resistance to
streptomycin also seem to be restricted to two regions.
Phenotypically, streptomycin-resistant mutants can be
divided into two classes, those resistant to streptomycin
but able to grow in its absence (Smr) and those whose
growth depends on continued presence of streptomycin
(Smd).Both classes of mutants have alterations in the
rpsL gene.Since most of the mutations causing
streptomycin resistance occurred in the rpsL gene,
(Salles et al 1992; Kenney et al 1994; Bjorkman et al
1999) it seemed logical that to decipher the streptomycin17
Figure 2 1.Similarities in the S12 protein from various
bacteria.This alignment was done using omiga software.
Each amino acid is represented in a different colored box.
This facilitates comparison of amino acid sequences from
all the bacteria.Several pockets of consensus sequences
are evident, for example, amino acids 1 to 20 and 41 to
120.These are the consensus sequences targeted for
designing primers as explained in the text.Amino acid 1
starts with the amino terminal and this figure is based on
the single amino acid code.The bacteria listed (in the
order of the tabulation) are, Borrelia burgdorferri,
Helicobacter pylori, Micrococcus luteus, Mycobacterium
tuberculosis, Staphylococcus aureus, Streptococcus
pneumoniae and Salmonella typhimurium.Bbui'tgeortufri
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resistance in S. gordonii, the S12 gene in S. gordonii
should be examined first.
Materials and Methods
Strains of S. gordonii
The strains of S. gordonii chosen for this study
should help elucidate the differences in streptomycin
resistant and streptomycin sensitive strains (Figure
2.2).The parental S. gordonii Challis strain, V288 is a
well-studied strain, which is streptomycin sensitive.
The Challis strain was made streptomycin resistant in the
laboratory, using methods described by Sambrook (1989).
The resistant strain is called GP204.Two other strains
were also used in this study, SP204 (1-1) and SP635.
Both these strains are streptomycin resistant S.
gordonii.SP204 (1-1) also is thymidine kinase deficient
by virtue of a point mutation in the thymidine kinase
gene.The GP204 strain was exposed to mutational
techniques and this point mutation was selected with FudR20
in the laboratory (Chris Franke, SIGA Pharmaceuticals).
This strain was studied to-confirm that the mutation
causing streptomycin resistance was stable, and not
affected by laboratory passages on the bench.Thisstrain
was also derived from V288.The strain SP635 contains
the C repeat region of S. pyogenes integrated behind a
promoter in the S. gordonii chromosome.These strains
are detailed further in Figure 2.2.
PCR
Primers Used
The primers used in the PCR reaction, CF56, CF57and
CF58 were designed from the conserved regions of the rpsL
gene.The rpsL genes from various bacteria were compared
and the conserved regions identified.The direction of
primer CF56 is downstream.The primers CF57 and CF58 are
primers going upstream.These primers contain degenerate
bases at several positions.The design of these primers
is indicated in Figure 2.3.21
Figure 2.2. The strains of S. gordonii used in this study.
The strain V288 is the "Challis" strain of S.gordonii,
which is the wild type streptomycin sensitive strain.The
rest are laboratory strains derived from V288,with
various added features, as indicated.V288
Challis Strain
No antibiotic
Resistance.
GP204
Streptomycin
Resistant
Figure 2.2.
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Figure 2.3. Designing of primers CF56, CF57 and CF58.The
nucleotide sequences of the S12 gene of Bacillussubtilis,
Staphylococcus aureus and Streptococcus pneumoniae shown
in the three pages.The sequences align very well.The
consensus sequence is shown with thelocation of the 3
primers situated in the consensus sequence. The primer
from 170 to 190 in the 5' strand is the primer CF56.The
primers CF57 and CF58 overlap and are situated in the 3'
strand.The primer from base pair 361 to 380 is CF58 and
the primer from 366 to 387 is CF57.24
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The nucleotide sequences of the primers arelisted in the
Appendix.
Chromosomal DNA
Five milliliters of an bacterial overnightculture,
5 ml was pelleted and suspended in 5041of water.This
tube was placed in a boiling water bathfor 10 minutes.
The tube was centrifuged for 10 minutes at15K rpm. The
supernatant containing the chromosomal DNA wascollected
and quantitated using a fluorimeter andvisualized on an
agarose gel.
Except when stated, all steps were carriedout using
standard procedures (Sambrook et al., 1989).PCR
reactions contained 20 pmol of each primer,CF56 and CF57
or CF58 and120 ng of chromosomal DNA in the
manufacturer's buffer.The PCR used 3 units of Pfu
thermostable DNA polymerase (Promega, Madison, WI)in
over 30 cycles of 94°C for 30seconds, 50°C for one minute
and 72°C for 2 minutes.A pre-incubation cycle, with94°C
for 1 minute, 47°C for 1 minute and 72°C for 2minutes was29
performed.The PCR product was cleaned using aQIAQuick
kit and then sequenced.
Multiplex restriction site PCR (mRS PCR)
Three downstream primers (RV1D, RV2D, RV3D)and
three upstream primers (RV1U, RV2U, RV3U) fromthe known
sequence of the gene were designed.The relative
orientation of these primers is shown in Figure2.4.The
primer on the unknown gene is a degenerateuniversal
primer with a restriction enzyme site.More than one
restriction enzyme primer can be used in one reaction,
thus improving the probability of a successful genewalk
(Sarkar et al., 1993).The outline of this method is
given in Figure 2.5.The sequences of all the primers
are listed in the Appendix.
200 pmol of the specific primer RV1D and 20pmol of
the restriction site primers were used in a 20Al
reaction.About 200 ng of the genomic DNA, 200 AM of30
Figure 2.4.Formulation of primers for mRS PCR.This DNA
was obtained as the PCR productof the primers CF56 and
CF57 on the S. gordonii genomic DNA.The primers used in
the mRS PCR gene walk are designed fromthis 210 by DNA.
RV1D, RV2D and RV3D denote primersdesigned to provide the
downstream sequences in the gene walk and RV1U,RV2U, and
RV3U are the primers to amplify the upstreamsequences.
The complete sequences of these primers aregiven in the
Appendix.31
CT CGT GT AGGAACAAT GACACCTAAAAAACCTAACT CTGCCCT TCGTAAAT T TGCTCGTGTACGTT TGAGTAACT TGAT CGAAGTAACTGCT T AT ATCCCAGGTATCGGACACAACT
GAGCACATCCT T GT 1 ACT GT GGATTTTTTGGAT TGAGACGGGAAGCAT T TAAACGAGCACATGCAAACT CAT TGAACTAGCT T CAT TGACGAATATAGGGT CCATAGCCTGT GT T GA
Ob A 40b 61b M Mb
RV1D MOD
MMMMIMM*--
TGCAAGAGCACAGTGT T GT GCT T CT TCGT GGT GGACGT GTW.AGACCT TCCAGGGGTACGTTACCATATCGTTCGTGGT GCGCTTGATACTGCTGGNGT TA
ACGT T CT CGTGTCACAACACGAAGAAGCACCACCT GCACAT T T TCTGGAAGGT CCCCATGCAAT GGTATAGCAAGCACCACGCGAAC'T ATGACGACCNCAAT
120b 140b 10 18813
RUJO
RV1I1
Figure 2.4.32
Figure 2.5. The various steps in multiplexrestriction
site PCR.RV1D, RV2D AND RV3D denote primersdesigned to
fetch the downstream sequences in the genewalk and RV1U,
RV2U, and RV3U are the primers to amplifythe upstream
sequences.The sequences of the primers are givenin the
appendix.33
RV1D RV2D RV3D
-->-->- ->-
<----fa-4(---* -4E----*
RV3URV2U RV 1 U
PCR with RV1D and All Restriction primers
1
PCR with RV2D and All Restriction primers
Sequence with RV3D for the downstream sequence.
Repeat with RV1U, RV2U and RV3U for
upstream sequences.
Figure 2.5.34
dNTP and 1.5 mM of MgC12 and 0.5 units of Amplitaq(Perkin
Elmer, Branchburg, New Jersey) completed thereaction.
Forty cycles comprised of 94 °C for 1 min, 55° C for 2min
and 72°C for 3 min, were conducted.Then 1 Al of this end
product was the template for PCRII.PCRII is similar to
PCRI and RV2D was used in lieu of RV1D.The PCR product
was cleaned and sequenced with RV3D.The same reactions
were repeated with specific primers RVIU,RV2U and
RV3U(PCR methods and applications(318-322:1993)).
Sequencing
All the sequencing was done at The Center for Gene
Research and Biotechnology (CGRB) central services lab at
Oregon State University.This facility uses the
enzymatic method of DNA sequencing (Sanger et al, 1989).
The sequences thus obtained were analyzed in the software
program DNAid and Omiga.These software help in aligning
the sequences, and also in translating the sequences and
other such functions.35
Cloning
The aim of this experiment was to clone the rpsL
gene into the bacterium to observe the phenotypes(Figure
2.6).A plasmid was designed for this purpose.The
plasmid pTRKH2 was selected, as this plasmid was most
suitable to transform into S. gordonii (O'Sullivan et
al., 1992).The plasmid pTRKH2 contains the erythromycin
resistance gene as marker and gram-positive and gram-
negative origins of replication.This plasmid does not
contain a gram-positive promoter.The promoter 635 from
S. gordonii,(Christine Franke and Tove' Bolken, Siga
Pharmaceuticals, personal communication), which is 239 by
long, was isolated from the S. gordonii chromosomal DNA,
using the primers RVprml and RVprm2.As large quantities
of the S12 protein is mildly toxic to the cells (Timms et
al., 1993), a hairpin loop was integrated at the
beginning of the promoter such that the transcription and
translation of the transformed gene was low.The
promoter DNA and the plasmid were ligated such that the
promoter was ligated in front of the multi-cloning site
(MCS) of the plasmid in the 5' -> 3' direction, between
the BglII and BamHI sites.The rpsL gene from the36
various strains of S. gordonii was pulled out using the
primers pTRKPstI and pTRKBamEI -(sequences in the
Appendix) using PCR based methodologies.The plasmid
pTRKH2 with the gram-positive promoter and the rpsL gene
were each cut with restriction enzymesPstI and BamHI.
The rpsL gene was ligated into the MCS.The rpsL gene
from the strain V288 was transformed into the strain
GP204 and the rpsL gene from GP204 was transformedinto
V288.The transformed bacteria were first selected on
erythromycin (5 ug/m1) and then selected on streptomycin
(500 pg/m1).Selection on two antibiotics in the same
step caused undue stress on the bacterium and hence a
single selection at a time was used.37
Figure 2.6. Steps in cloning and transforming therpsL
gene from streptomycin resistantand streptomycin
sensitive S. gordonii strains.All restriction enzymes
wee from New England Biolabs andused with manufacturer's
buffers.38
Cloning
Chromosomal DNA + RV PRM1, RVPRM2
1111Cut with ICut with BglII, PstI
PCR
239 BP Promoter 635
Bg1II, PstI
LIGATE
pTRKH2+PRM
BP
RVPTRKPSTI rpsL
Chr DNA Cut with PstI, BamHI
RVPTRKBAMHI Cut with LIGATE
PstI, BamHI
Ptrkh2 + PRM+ rpsL gene
Figure 2.6.39
Results
The genomic DNA from strains V288, GP204, SP204 (1-
1), and SP635 were subjected to PCR using the primers
CF56 and CF57 or CF58.The gel analysis showed identical
PCR products as seen in Figure 2.7.These PCR products
upon sequencing, gave a 210 base pair DNAfragment, which
was identical in all the four differentstrains of S.
gordonii.The 210 by fragment sequence is shown in
Figure 2.8.This fragment aligned very well with the
known S12 sequences from various bacteria and
particularly, the S12 sequence from S. pneumoniae (Salles
et al., 1993), a related gram-positive bacterium.
Using this sequence, the primers for mRS PCR were
designed (Figure 2.4).The end product of mRS PCR is
visualized on a 1.2% agarose gel in Figure 2.9.Some of
the mRS PCR had multiple bands, probably because more
than one restriction primer formed products.When this
happened, each restriction primer was used separately and
the products analyzed further.These PCR products were
sequenced.Combining the sequences from the upstream and
downstream primers and the 210 by fragment from the40
Figure 2.7. 1% Agarose Gel with the PCR products of S.
gordonii strains with primers CF56 and CF57.This gel was
stained with ethidium bromide.Lane 1 had the PCR product
with V288 Challis" strain as the DNA template.In
lanes 2,3 and 4 were the PCR products with the GP204,
SP204(1-1) and SP635 templates respectively.Lane M was
the 1 kb DNA ladder (MBI Fermentas).Figure 2.7.
I
4142
Figure 2.8.The sequence from the PCR productusing primers
CF56 and CF57.These sequences were identical in the
streptomycin sensitive V288 and the streptomycinresistant
strain GP204, except for a single base, an A toC, which
is highlighted.The first row is the sequence from the
strain V288 and the second row is from the strainGP204.43
CTCGTGTCGGAACTATGACACCTAAAAAACCTAACTCTGCCCTTCGTAAATTTGCT
111111111111111111111111 1111111111111111111111111111111
CTCGTGTCGGAACTATGACACCTACAAAACCTAACTCTGCCCTTCGTAAATTTGCT
CGTGTACGTTTGAGTAACTTGATCGAAGTAACTGCTTATATCCCAGGTATCGGACA
11111111111111111111111111111111111111111111111111111111
CGTGTACGTTTGAGTAACTTGATCGAAGTAACTGCTTATATCCCAGGTATCGGACA
CAACTTGCAAGAGCACAGTGTTGTGCTTCTTCGTGGTGGACGTGTAAAAGACCTTC
11111111111111111111111111111111111111111111111111111111
CAACTTGCAAGAGCACAGTGTTGTGCTTCTTCGTGGTGGACGTGTAAAAGACCTTC
CAGGGGTACGTTACCATATCGTTCGTGGYGCGCTT
11111111111111111111111111111
CAGGGGTACGTTACCATATCGTTCGTGGY
Figure 2.8.44
Figure 2.9. 1.2% agarose gel showing the end products of
mRS (multi restriction site) PCR.The gel was stained
with ethidium bromide.The template DNA used were the
V288 and GP204 strains of S. gordonii.The primers used
in mRS PCR I and II are RV1U and RV2U respectively.The
lanes are marked on the gel.The last gel has a 1-10 Kb
ladder (MBI Fermentas).Figure 2.9.
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earlier PCR using primers CF56 and CF57, theentire rpsL
gene sequence was reconstructedvia gene walking
techniques.The gene sequences of the four strains are
given in Figure 2.10.
The primers RVrps15' and RVrpsl3' weredesigned so
that the full gene can be amplifiedusing PCR and the
sequence confirmed.The primers' sequences are given in
the Appendix. These sequences were analyzedand the
differences between the streptomycin resistantand
streptomycin sensitive strains were thuselucidated.
In transformation experiments, the strainV288
transformed with the rpsL gene of GP204 remained
streptomycin sensitive.The streptomycin resistant GP204
strain transformed with the rpsL gene ofstrain V288
became streptomycin sensitive.The number of colonies
from this transformation was less and colonies,which
were resistant to lowerconcentrations of streptomycin,
were also found.47
Figure 2.10. The sequence of S12 gene from thestrains
V288, GP204, SP204 (1-1) and SP635 of S.gordonii.The
sequence, which contains thecoding sequence alone, has
414 base pairs.The sequences are identical except for
the single base change, a point mutation in thebase 167.
The sequence in blue script is the sequenceof the S12
gene from the S. gordoniistrain V288.The sequence in
green represents the S12 gene fromthe strain GP204, black
from SP204 (1-1) and red from SP635.The region of
interest is in bold letters.48
Accession Number:
ATGCCTACAATTAACCAATTGGTTCGCAAACCGCGTAAATCAAAAGTAGAAAAATC
ATGCCTACAATTAACCAATTGGTTCGCAAACCGCGTAAATCAAAAGTAGAAAAATC
ATGCCTACAATTAACCAATTGGTTCGCAAACCGCGTAAATCAAAAGTAGAAAAATC
ATGCCTACAATTAACCAATTGGTTCGCAAACCGCGTAAATCAAAAGTAGAAAAATC
TAAATCACCAGCATTGAACGTTGGTTACAATAGTTTGAAACGTGTTCCAACTAACG
TAAATCACCAGCATTGAACGTTGGTTACAATAGTTTGAAACGTGTTCCAACTAACG
TAAATCACCAGCATTGAACGTTGGTTACAATAGTTTGAAACGTGTTCCAACTAACG
TAAATCACCAGCATTGAACGTTGGTTACAATAGTTTGAAACGTGTTCCAACTAACG
AAAGTGCACCTCAAAAACGTGGTGTAGCGACTCGTGTCGGAACTATGACACCTAAA
AAAGTGCACCTCAAAAACGTGGTGTAGCGACTCGTGTCGGAACTATGACACCTACA
AAAGTGCACCTCAAAAACGTGGTGTAGCGACTCGTGTCGGAACTATGACACCTACA
AAAGTGCACCTCAAAAACGTGGTGTAGCGACTCGTGTCGGAACTATGACACC.ACA
AAACCTAACTCTGCCCTTCGTAAATTTGCTCGTGTACGTTTGAGTAACTTGATCGA
AAACCTAACTCTGCCCTTCGTAAATTTGCTCGTGTACGTTTGAGTAACTTGATCGA
AAACCTAACTCTGCCCTTCGTAAATTTGCTCGTGTACGTTTGAGTAACTTGATCGA
AAACCTAACTCTGCCCTTCGTAAATTTGCTCGTGTACGTTTGAGTAACTTGATCGA
AGTAACTGCTTATATCCCAGGTATCGGACACAACTTGCAAGAGCACAGTGTTGTGC
AGTAACTGCTTATATCCCAGGTATCGGACACAACTTGCAAGAGCACAGTGTTGTGC
AGTAACTGCTTATATCCCAGGTATCGGACACAACTTGCAAGAGCACAGTGTTGTGC
AGTAACTGCTTATATCCCAGGTATCGGACACAACTTGCAAGAGCACAGTGTTGTGC
TTCTTCGTGGTGGACGTGTAAAAGACCTTCCAGGGGTACGTTACCATATCGTTCGT
TTCTTCGTGGTGGACGTGTAAAAGACCTTCCAGGGGTACGTTACCATATCGTTCGT
TTCTTCGTGGTGGACGTGTAAAAGACCTTCCAGGGGTACGTTACCATATCGTTCGT
TTCTTCGTGGTGGACGTGTAAAAGACCTTCCAGGGGTACGTTACCATATCGTTCGT
GGTGCGCTTGATACAGCAGGTGTTACTGATCGTAAACAAGGCCGTTCTAAATACGG
GGTGCGCTTGATACAGCAGGTGTTACTGATCGTAAACAAGGCCGTTCTAAATACGG
GGTGCGCTTGATACAGCAGGTGTTACTGATCGTAAACAAGGCCGTTCTAAATACGG
GGTGCGCTTGATACAGCAGGTGTTACTGATCGTAAACAAGGCCGTTCTAAATACGG
TACTAAAAAACCAAAAGCATAA
TACTAAAAAACCAAAAGCATAA
TACTAAAAAACCAAAAGCATAA
TACTAAAAAACCAAAAGCATAA
Figure 2.10.49
Discussion
Analyzing the gene sequences of GP204, SP204 and SP635,
all three sequences were found to be identical.The
GP204 sequence was used for further analysis.The
putative rpsL gene open reading frame of S.gordonii
contains 414 coding nucleotides including the stopcodon
and 136 amino acid codons.Comparing the sequences of S.
gordonii strains V288 and GP 204, they were different
only in the identity of the residue at the position167.
The sequence AAAAAA in V288 compares as ACAAAAin GP204.
In the S12 protein, the mutation AAA to ACAtranslated to
a change from lysine to threoninein the amino acid 56.
The nucleotide comparison is depicted in Figure 2.11A and
the comparison of the protein sequence in Figure 2.11B.
It was shown in E.coli thatSmd mutants involved a
change from proline to leucine at position 90 orglycine
to aspartic acid at 91.In Smr mutants the changes were
either a change from lysine to arginine at position 87 or
lysine to arginine, asparagine or threonine at 42
(Funatsu and Wittman, 1972, Yaguchi et al., 1975 and
Funatsu et al., 1977).50
Figure 2.11A. Comparison of the nucleotide sequencesof
S.gordonii strains V288 and GP204. Thefirst row to be
compared is GP204 and the lower row isV288.The area of
interest is highlighted and the aminoacid composition of
this region is given along the nucleotide sequence.
Figure 2.11B. The S12 protein sequences of S.gordonii
strains V288 and GP204 are analyzed by comparison.The
first row of amino acids represents the S.gordonii strain
V288 and the bottom row represents thestrain GP 204.The
lysine 56 of V288 is mutated to threonine in GP204,the
putative cause of streptomycin resistance.51
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AGGGGTACGTTACCATATCGTTCGTGGTGCGCTTGATACAGCAGGTGTTAC
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AGGGGTACGTTACCATATCGTTCGTGGTGCGCTTGATACAGCAGGTGTTAC
414
TGATCGTAAACAAGGC CGTTCTAAATACGGTACTAAAAAACCAAAAGCATAA
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TGATCGTAAACAAGGCCGTTCTAAATACGGTACTAAAAAACCAAAAGCATAA
414
Figure 2.11A.MPTINQLVRKPRKSKVEKSKSPALNVGYNSLKRVPTNESAPQKRGVATRVGTM
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MPTINQLVRKPRKSKVEKSKSPALNVGYNSLKRVPTNESAPQKRGVATRVGTM
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56
KPNSALRKFARVRLSNLIEVTAYIPGIGHNLQEHSVVLLRGGRVKDLPGVRYHIVR
I1111111111111111111111111111111111111111111111111111111
KPNSALRKFARVRLSNLIEVTAYIPGIGHNLQEHSVVLLRGGRVKDLPGVRYHIVR
137
GALDTAGVTDRKQGRSKYGTKKPKA
1111111111111111111111111
GALDTAGVTDRKQGRSKYGTKKPKA
137
Figure 2.11B.53
In Mycobacterium tuberculosis, streptomycin resistance
was caused by the lysine codon in position43 to arginine
(Honore and Cole, 1994).In another study, 41
streptomycin resistant M. tuberculosis strains were
studied and 49% were attributed to a mutation in the rpsL
gene. In these, 70% were changes in lysinecordon 43
(Finken et al., 1993; Meier et al., 1994).In M.
smegmatis, streptomycin resistance was attributed to
lysine 43 and lysine 88 (analogous to 42 and 87
respectively in E.coli)(Kenney et al., 1994).
Streptococcus pneumoniae str41 allele, which has high
streptomycin resistance, has been well studied as a
reference marker.The str 41 mutations corresponded to a
single base substitution, converting lysine (AAA) to
threonine (ACA) at position 56 (Salles et al., 1992),
similar to our observed results.
Comparing the sequences of E. coli and S. gordonii,
conserved regions are seen, as shown in Figure 2.12. The
predicted S12 protein of S. gordonii is 68% identical to
E. coli S12 protein and 95.7% identical to S. pneumoniae
S12 protein. This is seen in Figure 2.13, where the S12
protein of S. gordonii and S. pneumoniae are compared.54
Figure 2.12.Analyzing the protein sequence of the S12
protein of S. gordonii (V288) and the S12 protein of
E.coli.
The E. coli sequence is from the genbank accession no
V00355.Ec denotes the E.coli S12 protein sequence and Sg
symbolizes the S. gordonii V288 S12 sequence.The dotted
lines in the E.coli (--) denote gap in the sequence to
optimize the alignment.The lysine 56 to threonine change
corresponding to the streptomycin resistance is indicated
by the bold typeface.55
SgMPTINQLVRKPRKSKVEKSKSPALNVGYNSLKRVPTNESAPQKRGVATRVGT
1:111111111 II III 111111111 1
EcMATVNQLVRKPRARKVAKSNVPALEAC PQKRGVCTRVYT
(T) 56
SgMTPKKPNSALRKFARVRLSNLIEVTAYIPGIGHNLQEHSVVLLRGGRVKDLP
11111111111 1111:1 III11111111111111:11111111111
EcTTPKKPNSALRKVCRVRLTNGFEVTSYIGGEGHNLQEHSVILIRGGRVKDLP
42
137
SgGVRYHIVRGALDTAGVTDRKQGRSKYGTKKPKA
111111111111 11111111111111111
EcGVRYHTVRGALDCSGVKDRKQARSKYGVKRPKA
124
Figure 2.12.56
Figure 2.13. Comparison of the S12 protein sequence of S.
gordonii (V288) and the sequence of S12 protein of
S.pneumoniae. The first row, labeled Sp, represents the
Sl2protein sequence from S. pneumoniae.The row marked Sg
is the S12 protein sequence of S. gordonii V288 strain.
There is over 95% homology between the S12 sequences.57
SpMPTINQLVRKPRKSKVEKSKSPALNVGYNSHKKVQTNVSSPQKRGVATRVGT
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SgVRYHIVRGALDTAGVTDRKQGRSKYGTKKPKA
137
Figure 2.13.58
The amino acid 56 of S. gordonii corresponded to the
amino acid 42 in E. coli.The amino acid 42 (lysine) in
the E.coli S12 sequence which when replaced by one of the
three amino acids arginine, asparagine or threonine
results in high level streptomycin resistance (Tubulekas
et al., 1991). It can be concluded that the mutation in
lysine 56 is similar to the mutation in lysine 42 of E.
coli.
The lysine to threonine mutation in S. gordonii
apparently causes streptomycin resistance as three
independent isolates all contained the same mutation.
This follows what has been seen in many other bacteria.
As the S12 protein is a conserved protein and essential
for bacterial viability, it is important that no mutation
disrupts its function.As seen in the literature review,
some of these mutations in the lysine cause hyper
accurate translation or slow rate of elongation and
leading to slower growth (Kashiwagi et al., 1998)(Saito
et al., 1994)(Timms et al., 1993).In E. coli, the
change of lysine to arginine was non-restrictive.The
mutation of lysine to threonine showed modest increase in
doubling time, from 42 minutes to 54.7 minutes (Tubelekas
et al., 1993).The elongation rate (amino acids/sec) was59
12.6 for the wild type and 8.9 fcr the mutant, which had
lysine 42 to threonine (Tubulekas et al., 1993).Looking
at this data and from our observations, we can speculate
that this mutation in S. gordonii does not cause any
debilitating effect on the bacterium, in the absence of
drug selection.
The streptomycin sensitive wild type strain V288
remained streptomycin sensitive when transformed with the
rpsL gene from the streptomycin resistant strain GP204.
This confirmed the observations seen in literature that
the streptomycin sensitive wild type is dominant.
Similarly, the streptomycin resistant GP204 strain, when
transformed with the wild type rpsL gene, became
streptomycin sensitive.Due to the low number of
colonies isolated and due to the presence of colonies
that are resistant to streptomycin in lower
concentrations, this experiment needs to be repeated in
the future, to clarify these results.
In summary, there is a mutation in amino acid 56 of
the S12 protein of S. gordonii changing lysine to
threonine. This mutation apparently causes streptomycin
resistance in the bacterium.This mutation in S1260
protein follows a pattern seen in the S12 proteinsfrom
other streptomycin-resistant bacteria.CHAPTER 3
STREPTOMYCIN RESISTANT MUTANTS IN
STREPTOCOCCUS PYOGENES
Introduction
61
Streptococcus pyogenes is a gram-positive pathogenic
bacteria.It causes a wide spectrum of diseases, from
pharyngitis (or sore throat) to rheumatic fever,
glomerulo nephritis and necrotizing fasciitis.It is
difficult to determine what causes one individual to have
a simple sore throat and for another individual to
develop rheumatic heart disease.Although particular
strains are correlated with a certain disease type, it is
still not totally predictable.The bacterium has a vast
repertoire of antigens and more than 200 serotypes exist.
The most important of these antigens is the M protein.M
protein has been discussed in the Introduction.Two
important factors in S. pyogenes pathogenicity are the M
protein and the bacterial adhesion to the pharyngeal cell
or the ease with which the bacterium attaches to the
throat.Adhesion plays a key role in the bacterial
pathogenicity.In order to be a successful pathogen, S.62
pyogenes has to attach to the throat epithelial cellsand
multiply before the immune system of the host attacks it.
The adhesion is particularly important because without
adhesion, the bacterium will be readily eliminated by the
innate immune system of the host.The amount of M
protein present defines pathogenicity.The presence or
absence of the M protein and the amount of M protein on
the cell surface also determine the antigenic serotype of
the organism.Thus these two factors give an indication
of pathogenicity in S. pyogenes.In this study, these
two factors are tested as signs of virulence in
streptomycin resistant S. pyogenes strains.
Materials and Methods
Strains Used
The S. pyogenes strains used in this study are the
S43ATCC, S43/192/4, S43/192/4P8, and S43/192/30R strains.
The S43ATCC strain was the S43 strain from the ATCC
stock.The S43/192/4 is a S. pyogenes strain from the
Rockefeller collection.This strain was made63
streptomycin resistant and referred to as S43/192/4SmR.
S43/192/4P8 is the S43/192/4SmR strain, which was
passaged 8 times in mice.S43/192/30R referred to in
this study is another strain of S. pyogenes from the
Rockefeller collection.This strain is streptomycin
resistant.These strains are listed in Table 3.1.Dr.
Kevin Jones of SIGA Pharmaceuticals kindly provided these
strains.
Colony Morphology
The strains were streaked on BHI agar (DIFCO) with
suitable antibiotics.BHT is brain heart infusion to
which is added 10% agar.Blood agar (BA) plates with
antibiotics were also used.These blood agar plates were
useful in monitoring hemolysis.With S43ATCC strain, no
antibiotics were used.For all the streptomycin
resistant strains, 500µg /ml of streptomycin614
Table 3.1. Shows the strains used in thisstudy.SmR
denotes streptomycin resistance and when nosymbol is
present, it denotes the wild type (nostreptomycin
resistance).Other additional features are mentioned.65
strains
Streptomycin
Resistance Source
Additional
Features
S43 ATCC ATCC
S43 ATCC SmR + Lab Strain
Strain was
made
streptomycin
resistant in
the lab
following
standard
procedures a-
S43/192/4
Dr. K Jones
Rockefeller
Collection b.
543/192/4
SmR
+ Lab Strain
Strain was
made
streptomycin
resistant in
the lab
following
standard
procedures a
S43/192/4 P8
+ Lab Strain
S43/192/4
SmR was
passaged in
mice 8 times
C
Table 3.166
S43/192/30R +
Dr. K Jones
Rockefeller
Collection b.
8-Reference Sambrook et al.,1989.c- Dr.K. Jones (Siga
b-Siga Pharmaceuticals
Table 3.1.(Contd)
Pharmaceuticals)67
was added.The plates were incubated at 37°C for 48
hours.
Polymerase Chain Reaction (PCR)
The PCR was done as described in Chapter 2.The
primers CF56 and CF57 were used in the first study and
part of the S12 gene was sequenced.Using the primers
TT1 and TT2 the full gene was recovered and sequenced.
The sequences of the primers are given in the appendix.
ImmunoBlot
The test strains were streaked on BHI plates with
appropriate antibiotics and incubated overnight.A
nitrocellulose membrane was applied on the plate for 20
minutes at room temperature.Then the membrane was
incubated for 30 minutes at 37°C and for 15 minutes at
80°C.The membrane was blocked for 30 minutes with TBS
(Tris buffered saline) to which 3% gelatin was added.
The membrane was decanted and covered with TTBS (Tween2068
wash solution in TBS)and shaken in a orbital shaker for
30 minutes.20 ml of TTBS with 1% gelatin was added to
40 !al of 10F5, an anti M6 monoclonal antibody, and
incubated at room temperature for 3 hours.The membrane
was washed 3X with TTBS, and 20 ml of TTBS with 6.6 µl of
secondary antibody conjugated with alkaline phosphate was
added.This was incubated for 2 hours.The blot was
washed twice with TTBS and once with TBS.The blot was
then developed using the color developer solution.
ELISA (enzyme linked immunosorbent assay)
Competition ELISA was used to quantitate the amount
of the M protein on the surface of the bacterium.The
bacterial cells were prepared as described below and were
reacted with a known amount of anti-M antibody.The anti
M antibodies used were the monoclonal antibodies 10F5 and
10B6 (Jones et al., 1985).SIGA Pharmaceuticals provided
these antibodies.The antibody, which was not bound to
the antigen on the bacterial surface, was titrated
against known concentrations of purified M protein.69
The bacterial cultures were grown to Ti65Orm, of 0.6
0.7.The cultures were then centrifuged, washed and
resuspended in PBS (+0.02% sodium azide).To kill the
cells, the cultures were placed at 56°C for 60 minutes.
After washing and centrifuging, the 0.D was adjusted to
1.0.These normalized cells were used in the competition
ELISA.
In a V-bottom microtitre wells, 75 !al of PBS/Brij was
dispensed in columns 2 -12.150 W_ of the bacterial
suspension was added to the first well of each row in
triplicate.Doubling dilutions down each row were
performed by sequentially transferring 75 !al from the
first wells to each succeeding well.75 1.1.1 of the
antibody was added and rotated at 4°C overnight.A flat
bottom plate was coated with 100 ill diluted antigen in
carbonate buffer (containing 0.02% sodium azide) and
incubated at room temperature overnight.The antigen was
removed from the flat bottom plate and washed 5X with
PBS/Brij.The plate was blocked using 2% BSA in PBS/Brij
for 1 hour at 37°C.The V- bottom plate was centrifuged
for 15 min at 2000 rpm.The flat bottom plate was
emptied and 50 µl from each well in the V bottom plate was70
transferred carefully tc the flat bottom plate.The flat
bottom plate was incubated for 3 hours at 37°C.Then the
plate was emptied and washed 6X with PBS/Brij.50 gl of
goat anti mouse secondary antibody (alkaline phosphatase
conjugate) at 1:1000 dilution in PBS/Brij was added and
incubated at 37°C for 2 hours.The plate was emptied and
washed 5X.The plate was developed with 200 gl
phosphatase substrate (Sigma) at 1 mg/ml in 10%
diethanolamine/3 mM MgC12 (pH 10.0).The plate was read
at 405 nm (Pozzi et al., 1992).The carbonate buffer,
PBS, and other buffers used were prepared following
standard procedures (Sambrook et al., 1989).
Pharyngeal cell adhesion
The overnight cultures of the S. pyogenes strains
were washed twice with PBS containing 1mMCaC12 and 2mM
MgC12).The bacterial cells were normalized at A650 to 1.
The control strain is the S. pyogenes strain
(henceforth referred as the "luci" strain") containing
the plasmid pCSS945.This plasmid contains the lucGR71
gene from Pyrophorus. plagiothalamus andis
chloramphenicol resistant (Loimaranta et al., 1998).
Thus, the luci strain contains and expressed the
luciferase gene in it.
The pharyngeal cells (pharyngeal carcinoma cell
line, Detroit 562 ATCC CLL 138), were plated on a 16 well
plate and washed with HEPES minimal essential media
supplemented with 10% fetal calf serum.Various
dilutions between the test strains, the luci strain and
the medium were made. The dilutions were put on cells for
3 hours.The cells were washed with PBS(+ CaCl2 and
MgC12).To each of the wells was added 250 pi of D-
luciferin (1mM D-luciferin in 100 mM sodium citrate
buffer, pH 5.0).The plate was read immediately and the
competitive adherence of the test strain against the luci
strain and the resultant luminescence was measured.
Electron Microscopy
The overnight cultures of the bacterial strains were
centrifuged at 3000Xg for 10 minutes.The pelleted cells72
were washed thrice with PBS and then were suspended in
PBS at 1010 cells/ml.varying concentrations of the
monoclonal antibody 10F5 were added.The ratio of 100 111
of the cell and 100 piimi of the antibody worked best.
After incubation at 37°C for 60 minutes, the cells were
centrifuged for 10 minutes at 1000Xg.The cells were
washed with PBS to which is added 0.5% BSA.The final
cell pellet was resuspended in 50 µl of PBS.The
secondary antibody reaction with gold attached anti mouse
IgG was set up in the ratio of 50:1 for 60 minutes at
37°C.The cells were washed, centrifuged and resuspended
in 100 pi of PBS.These cells were added on a copper grid
and the excess liquid blotted away and viewed under the
electron microscope (Demuth et al., 1989).
Results
The colonies of the different strains of S.
pyogenes, S43 ATCC, S43/192/4 SmR, and S43/192/30R were
observed on the plates.All the three strains are
streptomycin resistant and streaked on BHI plates with73
5004g/ml.As seen in Figure 3.1, the colonies of
S43/192/4 and S43/192/30R are strikingly different.
S43/192/4 forms small, regular, convex white colonies.
The 30R strain and the S43 strains form large mucoid
colonies, which on further incubation becomes flat and
dry.On blood agar plates, all the strains of S.
pyogenes showed f3- hemolysis.
The genomic DNA of the various strains of S.
pyogenes was subjected to PCR using the primers TT1 and
TT2.These primers were designed from the putative
sequence of the rpsL gene of S. pyogenes from the genbank
database (Chris Franke, SIGA Pharmaceuticals).After the
S12 gene was amplified using PCR and cleaned using the
QlAquick kit, these PCR products were sequenced.The
sequences of streptomycin sensitive S43ATCC strain and
streptomycin sensitive S43/192/4 were identical. The
streptomycin resistant strain of S43ATCC, which was made
streptomycin resistant in the lab using standard
procedures, was also sequenced and the comparison between
the streptomycin sensitive and resistant S43ATCC is given
in Figure 3.3.74
Figure 3.1.The S. pyogenes strains S43ATCC SmR,
S43/192/4 SmR and S43/192/30R streaked on a BHI plate
with the antibiotic streptomycin (500 4g/m1). The plate
was incubated at 37 °C for about 36 hours.The difference
in the colony morphology is seen with the strains S43ATCC
and S43/192/30R forming mucoid colonies whereas the
S43/192/4 SmR strain forms convex, small, white and
regular colonies.
In the plate,1 denotes S43/192/4 SmR,2 as the S43 ATCC
strain and 3 denotes the strain S43/192/30R.i
Figure 3.1.
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Figure 3.2. A 1% agarose gel pictureshows the products
of the PCR with the genomic DNA ofS43/192/4 SmR,
S43/192/30R as template DNA with TT1 andTT2 as the
primers.This gel was stained with ethidiumbromide.
The lanes are labeled in the gel.Figure 3.2.
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The streptomycin resistantS43/192/4 and S43 ATCC were
compared and the difference in theputative S12 gene
noted, as shown in Figure 3.4.The sequences of the
streptomycin resistant strains 543/192/4and S43/192/30R
were also compared and thedifferences between various
strains are tabulated in Table 3.2.The 30R strain has a
point mutation in the 56th amino acid codon,changing the
lysine to threonine.In the S43/192/4 SmR strain, there
are two mutations whencompared to the wild type S.
pyogenes.One point mutation changed the lysinein 56 to
arginine.The second mutation caused the lysine inthe
amino acid 101 to asparagine.The strain S43 /192/4P8 is
the streptomycin resistant animal passagedS43/192/4.
This strain was identical to S43/192/4with respect to
the S12 gene (Figure 3.5).
An immunoblot was done with these strainsto check
the production of the M protein andthus assess the
potential pathogenicity of the strains.A monoclonal
antibody, 10F5 was used in this blot.As this blot shows
in Figure 3.6, the streptomycin resistantstrains
S43/192/4 and S43/192/30R have M protein intheir outer
cell membrane.79
Figure 3.3. The S12 sequences of S43ATCC strains, both
streptomycin resistant and streptomycin sensitive strains
are aligned and compared.The streptomycin resistant
strain was made in the lab following standard procedures.
This S43 ATCC SmR strain has the lysine 56 replaced by
the amino acid isoleucine. The streptomycin resistant
strain is denoted as SmR and streptomycin sensitive
strain as SmS.80
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SmSGVRYHIVRGALDTAGVADRKQGRSKYGAKRPKG
Figure 3.3.81
Figure 3.4.The streptomycin resistant strainsof S.
pyogenes, S43/192/4 SmRand S43 ATCC SmR were analyzed.
In S43 ATCC SmR strain, thelysine56 was mutated to
isoleucine.The mutation of this amino acid is very
frequent in S12 gene mutation instreptomycin resistance.
In S43/192/4 SmR, there are twomutations, in lysine 56
and 101.The strains are referred to as ATCCand 192/4
respectively.82
192 / 4 MP T I NQLVRKPRKS K I EKS DS PALN IGYNSHKKVQTKMAAPQKRGVATRVG
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
AT CCMP T I NQLVRKPRKS K I E KS D S PALN I GYNSHKKVQTKMAAPQKRGVATRVG
192/4TNT SAIRKFARVRL SNL I EVTAY I PGI GHNL QE HS VVL I RGGRVND PRKP1\
I I I IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
I
ATCCTM'IPIKPI'SALRKFARVRL SNL I EVTAY I PG I GHNL QE HS VVL I RGGRVED
137
192 / 4L PGVRYH I VRGAID TAGVADRKQGRS KY GAKRPKG
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
AT CCL PGVRYH I VRGAL D TAGVADRKQGRS KYGAKRPKG
137
Figure 3.4.83
Table 3.2. Tabulation of various mutations seen in the
strains of S. pyogenes.The streptomycin sensitivity and
the mutation if any in the amino acids lysine 56 and
lysine 101 are given.84
Strain
Streptomycin
resistance
Challenge
a
in Mice
Lysine 56Lysine 101
S43 ATCC Sensitive +
Wild type
(lysine)
Wild type
(lysine)
S43 ATCC
SmR
Resistant + Isoleucine Lysine
S43/192/4 Sensitive N.D Lysine Lysine
S43/192/4
SmR
Resistant ArginineAsparagine
S43/192/4
SmR P8 Resistant ArginineAsparagine
S43/192/30RResistant N.D Threonine
Lysine
T14b Resistant + Asparagine Lysine
aDr.K. Jones et al (1999) at SigaPharmaceuticals did
the mouse studies.Mice were infected intranasally with
the challenge strain and the virulence ofthe strain in
colonizing the throat, and in causing frankdisease were
recorded.
bThis strain T14 was studied by ToyerBolken at Siga
Pharmaceuticals.This strain is similar to S43/192/30R
in properties.
Table 3.2.85
Figure 3.5.Ancillary mutations in S. typhimurium, cause
avirulence, which are quickly overcome andthe second
mutation is compensated by yet another mutation.But, in
S. pyogenes strain S43/192/4, eight passagesin mice have
not reversed the ancillary mutation as seenin this
Figure.The strain still stayed avirulent.The first
sequence to be compared isS43/192/4 SmR, and the latter
is the strain S43/192/4P8.86
MP T I NQLVRKPRKS KI EKS DS PALNI GYNSHKKVQTKMAAPQKRGVATRVGTMT PR
IIIIIIIIIIIIIIIIIIIIIiIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
MP T I NQLVRKPRKS K I EKS D S PALN IGYNSHKKVQTKM.AAPQKRGVATRVGTMT PR
KPNSALRKFARVRLSNL I EVTAY I PGI GHNLQEHSVVL IRGGRVNDL P GVRYH IVR
11111111111111111111111111111IIIIIIIIIIIIIIIIIIIIIIIIIII
KPNSALRKFARVRLSNL I EVTAY I PGI GHNLQEHSVVL IRGGRVNDL P GVRYH IVR
GAL D TAGVADRKQGRS KY GAKRPKG
IIIIIIIIIIIIIIIIIIIIIIIII
GAL D TAGVADRKQGRS KYGAKRPKG
Figure 3.5.87
Figure 3.6.An immunoblot was done with S43ATCC strain as
the positive control, S. gordonii strain as thenegative
control.The anti M antibody 10F5 was used and the
immunoblot used alkaline phosphatase as the colormetric
agent.The anti mouse antibody was tagged with the
substrate.The strains used are indicated on the
membrane.Figure 3.6.
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Further, the M protein in the case ofS43/192/4 was not a
secreted protein, as the M protein patterndid not match
that of the secreted protein.
The competition ELISA graph seen isin Figure 3.7.
This graph was designed to show the %inhibition of the
strains.After adjusting for the blank, the readingin
each cell dilution was compared with theantibody alone
reading, which was designated at 100%.Thus the compared
percentages for every cell dilution of everystrain were
computed.The results as they were done intriplicate
were averaged and the graphplotted.The graph shows
that the S. pyogenes strain S43/192/4 SmRis almost
similar to the strains 30R and S43ATCC inthe 50%
inhibition rate.The negative control showed no
inhibition.
The pharyngeal adhesion assay testedfor the
presence of surface proteinsrequired for the adhesion of
the bacterium to the cell (Fluckiger etal., 1998),
(Loimaranta et al, 1998).A competition assay was set up
between the I'luci" cells containing theluciferase
plasmid and known to adhere to the pharyngealcells and
the strains tested.The ratio between the test strain
and the luci was varied and MEM was used asthe medium on90
Figure 3.7. The graph of a competition ELISA is seen.
The cells are increased in two fold dilutions.The data
is presented as % inhibition, that is the amount of M
protein present on the surface of the cell which binds to
a predetermined amount of the anti Mprotein monoclonal
antibody, 10F5 and the unbound residual antibody is
tittered. If the amount of M protein is more, the level
of antibody detected drops.120
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Figure 3.8.The pharyngeal assay measures thecompetition
in adhering to the pharyngeal cells bythe two strains,
the "luci" strain, which contains theluciferase plasmid
and the test S. pyogenes strain. Ifthe test strain does
not adhere at all or if its adherenceproperties are
less, then this data would show up in theluminescence
units and would be equal to the luci strainalone.R
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the cells.The results are depicted in the Figure 3.8.
The test strains were added in 100 gl and 200 gl and the
luci strain was added at a constant 100 gl per epithelial
cell well. The results from this experiment show that
S43/192/4 SmR and S43/192/30R strains adhere better than
S43 ATCC.There is trend in the adherence of S43/192/4
SmR being lesser than S43/192/30R, but the design of this
experiment did not allow for detection of subtle
differences.
The electron microscopy pictures in Figure 3.9 show
the presence of M protein on the surface of the S.
pyogenes strains.This experiment looked for the
presence of M protein on the surface of the bacterium,
any visual properties such as secretion after a time
point, less numbers in detectable range, and the
interaction of the M protein and the monoclonal antibody
10F5.The gold colloidal anti mouse antibody was used to
detect the monoclonal 10F5.The presence of gold
indicates the presence of M protein in S43 ATCC,
S43/192/4 SmR, and S43/192/30R strains.95
Figure 3.9. Electron microscope pictures ofthe various
strains of S. pyogenes.Goat anti mouse immunogold
antibodies were used to identify the anti Mmonoclonal
antibody 10F5, bound to the M protein onthe bacterial
surface. A denotes the strain S43 ATCC, Brefers to the
strain S43/192/30R, C refers to thestreptomycin
resistant strain S43/192/4 and D denotes thenegative
control strain S. gordonii GP204. Themagnification of
these pictures is 28K X, except for C,which has a
magnification of 35K X.Figure 3.9.
B
9697
Figure 3.9.(Contd).98
Discussion
Comparing the colony morphology of S. pyogenes
strains S43/192/30R, S43 ATCC and S43/192/4, S43/192/30R
and S43 ATCC colonies look similar. These colonies were
mucoid in appearance and become dry and flat later.This
is due to the production of the hyaluronidase enzyme and
this enzyme breaks the hyaluronic acid capsule and hence
the colonylooks dry.The strain S43/192/4 has white,
convex and regular colonies and these coloniesdo not
change over time. The S43/192/4 strain, hence is
different in either capsule formation or in surface
proteins due to this colony morphology.
Analyzing the sequences of the S12 gene of the
strains of S. pyogenes S43 ATCC and S43 ATCC SmR, it is
clear that the streptomycin resistance in the S43 ATCC
strain is caused by the point mutation in the amino acid
56.The lysine 56 is mutated to isoleucine.This is
unique because in most bacteria the lysine changes to
threonine, arginine or asparagine, although there is a
report of an stra mutant with a change to glutamine from
lysine 42 in E.coli (Funatsu and Wittman, 1972).This
mutation to isoleucine is interesting.In the strain99
S43/192/4, there are two mutations, one in lysine 56 and
another in lysine 101.Lysine 56 changes to arginine and
the lysine 101 to asparagine Jti streptomycin resistant
S43/192/4.This is significant because both the lysine
56 and 101 are the two hotspots for mutation in
streptomycin resistance in S12 gene in most bacteria.
The mutation occurs in either one of the spots leading to
streptomycin resistance but mutations in both the
hotspots have not been seen to our knowledge.
The S12 gene sequence of S. pyogenes and S. gordonii
V288 strain were aligned and were found to have over 90%
consensus (Figure 3.10).Thus the rpsL gene is conserved
within the family.
It was observed that the S43/192/4 strain is not
pathogenic in mice (K Jones, SIGA Pharmaceuticals 1999,
personal communication).This strain was used to
inoculate mice with S. pyogenes, but the mice did not
exhibit disease.In literature, it has been shown that
restrictive mutations in rpsL in S.typhimurium are
associated with a loss of virulence in mouse model system
(Bjorkman et al., 1998).In addition, virulence-
restoring compensating mutations arise with high100
Figure 3.10. The S12 gene sequence of S. pyogenesS43ATCC
strain and S. gordonii V288 strain are alignedand
compared.As seen, the two sequences have over 90%
consensus sequences.S. pyogenes is represented as Spy
and S. gordonii as Sg.101
Spy
MP T INQLVRKPRKS K I EKS DS PALM I GYNSHKKVQTKMAAPQKRGVATRVGT
111111111111111:11111111:11111:1 1111111111111111
MP T I NQLVRKPRKS KVEKS KSPALNVGYNSLKRVPTNESAPQKRGVATRVGT
S g
Spy
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111ii1111111111111111111111111111111111111111111111
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S gVRYHIVRGALDTAGVTDRKQGRSKYGTKKPKA
Figure 3.10102
frequency in the mouse, and all of this occurs in the
rpsL gene.But in S43/192/4, eight passages in mice did
not change the mutation or cause any other mutations, as
seen in the S43/192/4P8.Can the double mutation in the
S12 gene, the mutations in both the mutational hotspots
for nonrestrictive streptomycin resistance mutations,
lysine 42 and 87 in E.coli nomenclature, cause loss of
pathogenicity?That this kind of double mutation is
unique leads to this question of mutations causing stable
non-virulence in S. pyogenes.
Secondary structure predictions done on Omiga
software showed no significant change in the predicted
structure following the double mutation.
To explore the cause of non-virulence in S43/192/4,
the M protein of this strain was studied.The presence of
M protein was confirmed with the iinatunoblot.The
immunoblot also suggested that the M protein of S43/192/4
strain was not being preferentially secreted.
The competition ELISA graph shows that the amount of
M protein in S43/192/4 was not significantly different
from the amount of M protein in S43/192/30R and S43ATCC.
A trend was seen in one experiment where the S43/192/4
SmR was one fold less than the other strains. This103
experiment checks the M protein on the cell surface of
the strains and if the M protein is less and hence more
antibodies that bind the M protein were free to bind the
test protein and be detected. Though the statistical
significance of this observation, a single fold
difference, is debatable, this is an indication that the
strain S43/192/4 binds less anti M protein antibodies
than S43 ATCC and S43/192/30R streptomycin resistant
strains.
The pharyngeal cell adhesion assay tested for the
adhesins on the bacterium to host tissue.It has long
been speculated that M proteins may also act as adhesins,
but the mechanisms remain unclear.Other receptors
responsible for mediating streptococcal adherence include
fibroblasts, fibronectin binding proteins FBP54, and
SfbI/protein F (Navarre and Schneewind, 1999).The
binding of M protein is speculated to occur through the
C-repeat domains.This assay did not give consistent
results with the S. pyogenes strains.But the numbers
from these experiments indicate that the S43/192/4 SmR,
S43/192/30R, and S43 ATCC strains all adhere to the
pharyngeal cell membrane.It is evident that the
S43/192/4 strain is endowed with adhesion properties and104
the amount of adhesion and the differences between
S43/192/4, S43ATCC and S43/192/30R should be garnered
from different set of experiments.
The electron microscopy pictures suggest that the
S43 ATCC, S43/192/4, and S43/192/30R all have comparable
amounts of M protein on their cell surface.The M
protein on the surface of S43/192/4 binds the monoclonal
anti M protein antibodies.Hence that part of the M
protein that binds the antibody has not been altered
structurally or otherwise.
It has to be noted that all the experiments
designed, the ELISA, immunoblot, and the pharyngeal assay
zoned in the C repeat region of the M protein.The
monoclonal antibodies used in this study, 10F5 and
20B6,bind to a region in the C repeat domain. The
adhesive properties are speculated to be in the C repeat
region.Hence the variation, which might be in another
part of the M protein, needs to be studied further.
Ancillary mutations have been seen in E.coli (Timms
et al., 1993).But these ancillary mutations occurred in
SmDmutants, the strains dependant on streptomycin for
growth, not in SmR strains in this study.These ancillary
mutations in the SmpE.coli are hypothesized to give an105
increased growth rate in the transition from streptomycin
presence to absence, and hence increased viability.No
such advantages are seen in S43/192/4, though the theory
of the ancillary mutation giving an edge to the bacterium
is intriguing, and would explain the stability of the
ancillary mutation.The rate of occurrence of ancillary
mutations in rpsL is many orders of magnitude higher than
the expected rate (10-1eper base pair per replication), if
these mutations are independent of the primary mutation
(Timms et al., 1995)(Boe et al., 1992).The hypothesis
put forward is that the mutations in the rpsL gene are
not random, but are clustered. The rpsL gene region
experiences periodic episodes of hypermutation.Also,
the ancillary mutation may reflect the hypermutable
stress state triggered by the expression of the first
mutation.
In conclusion, streptomycin resistant mutants of S.
pyogenes were studied.Mutants S43ATCC SmR and
S43/192/30R were similar to other streptomycin resistant
mutants of S. gordonii and other bacteria and had a point
mutation in the S12 gene changing the lysine 56.The
S43ATCC SmR strain had an :Lsoleucine replace the lysine
56.This is a novel mutation and has not been seen106
before at lysine 56.The 543/192/4 strain had two
mutations, in lysine 56 and lysine 101.These two
mutations are in the two hotspots of mutation in the rpsL
gene. Most bacteria have a mutation in lysine 56 or in
lysine 101 leading to streptomycin resistance but not in
both.The experiments designed to study the M protein
and the adherence properties of S43/192/4 did not show
any abnormal results, though the amount of M protein in
S43/192/4 seems marginally less than the other strains.
Thus the non-pathogenicity of S43/192/4 SmR may be due to
a posttranslational modification of the M protein,
rendering it less antigenic.As the S12 protein is part
of the translational apparatus, these mutations may
affect more proteins and hence the pathogenicity also
(Curran et al., 1995) (Fujii et al., 1999) .The future
study of this strain S43/192/4, can target on some known
proteins of the bacterium, to decipher the cause for loss
of pathogenicity.As this study proved that the M
protein and adherence factors play a lesser role in
S43/192/4 strain's lesser virulence, other novel ideas
attributing to the avirulence should be considered and
tested. This information and the work done in this study
would throw light on the importance of the translational107
apparatus in virulence and provide yet anothermethod of
attenuating virulence in bacteria.It is also
interesting that the second mutation in S43/192/4 wasnot
repaired or a compensatory mutation incorporated as seen
in S. typhimurium (Bjorkman et al., 1989). Thisrelative
stability of the second mutation should also beexamined.
This study establishes that many different kindsof
mutation can lead to streptomycin resistance.But these
mutations occur in certain amino acids (42 and 87;E.
coli nomenclature) and only in one hotspot.Thus
mutation in one hotspot leads to streptomycinresistance,
but mutations in both lead to further repercussions as
loss of virulence.We already know that in E. coli,
translation abnormalities occur due to streptomycin
resistance (Timms et al., 1993). Hence the effect of a
double mutation should be studied, in the future.108
CHAPTER 4
CONCLUSION
Streptococcus pyogenes is a gram-positive coccus,
which causes a variety of diseases, includingrheumatic
fever.As an approach to a preventative vaccine, a
bacterial commensal vector expressing a conserved
antigen of this pathogen uses streptomycin resistance as
the antibiotic marker.Prior to entry into clinical
trials, it was important to determine the nature of
streptomycin resistance so that the potential safety of
the vaccine strain can be assessed.Using various PCR
based techniques, the rpsL gene of the vector
Streptococcus gordonii was isolated and sequenced.The
rpsL gene codes for the S12 protein of the ribosomal
complex and is important in translation.Streptomycin
resistance in S. gordonii was studied using the
streptomycin resistant strains GP204, SP204(1-1) and
SP635.SP635 is a vaccine strain, in which the C repeat
immunogenic region of Streptococcus pyogenes was
integrated into the chromosome.As predicted from
literature, the lysine 56 of the rpsL gene was mutated
to threonine in resistant strains.This mutation109
follows a pattern seen in many bacteria.Cloning this
gene and transformation into astreptomycin-sensitive
recipient showed that streptomycin resistance was not a
dominant trait.Presence of this resistance did not
alter the growth pattern of the bacterium, nor cause any
other unusual phenotypic characteristics.Hence it was
concluded that the streptomycin resistance caused bythe
point mutation changing lys 56 to thr was likely safeto
be used in vaccine strains.
Streptomycin resistance in Streptococcus pyogenes
was studied using PCR techniques.The streptomycin
resistant strains had mutations in the rpsL gene Two
strains had lysine 56 mutated to isoleucine and
threonine respectively.The mutation to isoleucine has
not been previously encountered.The strain S43/192/4
SmR had two mutations, one in lysine 56 and a second in
lysine 101, the two hotspots in streptomycin resistance
mutation.Animal studies demonstrated that this strain
was less virulent than wild type S. pyogenes.To
ascertain if the two mutations in rpsL gene was the
cause of loss of pathogenicity,the M protein on the
surface and the adherence properties of the strain was
tested.Competition ELISA showed no discernable110
difference in the levels of M protein.Adherence to
pharyngeal cells showed similar adhesion properties.
The M protein was also detected using immunogold
antibodies under the electron microscope.These also
did not show any difference.
The streptomycin resistance in S. pyogenes is
caused by mutations to the amino acid lysine 56.The
strain S43/192/4 showed unusual mutation at residue 101.
If the mutations in the two hotspots in the rpsL gene
cause avirulence, this phenomenon should be studied
further.It would be interesting to know this as this
will provide another potential method of attenuating a
virulent bacterium.The advantages offered by this
mutation should also be studied as the mutation is
stable and if the clustered mutation theory is correct,
this mutation will shed light on this theory.111
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CF 56
5' CTC GTG TWG GWA CAA TGA CAC 3'
CF 57
AAC WCC WGM AGT ATC AAG YGC 3'
CF 58
5' GMA GTA TCA AGY GCD CCA CG 3'
RV1D
5' ACC TAA CTC TGC CCT TCG TAA A 3'
RV2D
5' TGC TCG TGT ACG TTT GAG TAA C 3'
RV3D
TGT TGT GCT TCT TCG TGG TG 3'
RV1U
5' CGC RCC ACG AAC GAT ATG GTA AC 3'
RV2U
5' TAC AEG TCC AEC ACG AAG AAG C 3'
RV3U
GAT ATA AGO AGT TAC TTC G 3'
RVRSECORI
5' NNN NNN NNN NGA ATT C 3'
RVRSBAMHI
5' NNN NNN NNN NGG ATC C 3'
RVPRM1
5' GAA GAT CTT CGT CAG GGT GAA TAT TAE TAA 3'
RVPRM2
5' AAC TGC AGG TTA TCG ATT TTT AAT TAT T 3'
RVPTRKPSTI
5' AAC TGC AGA TGC CTA CAA TTA ACC AAT TGG T 3'120
RVPTRKBAMHI
5' CGG GAT CCC GTT ATG CTT TTG GTT TTT TAG T 3'
TT1
5' CAC CAA GTG CTA TAT CAA CC 3'
TT2
5' CTC TTA TCC CCT TCT ATT ATC C 3'
RVRPSL5'
5' CGG GGT ACC GAT GCC TAO AAT TAA CCT GGT TA3'
RVRPSL3'
5' CCC AAG CTT TTA TTA TGC TTT TGG TTT TTT AG3'